Lifevantage Corp Stock Price, News & Analysis

LifeVantage (Nasdaq:LFVN), a health and wellness company focusing on cellular health, has announced it will release its first quarter fiscal year 2025 financial results on October 29, 2024, after the stock market closes. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day.

Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers. A telephone replay will be available until November 12, 2024. Additionally, a live webcast will be accessible on the company's Investor Relations website, with an archive available for approximately 30 days.

LifeVantage (Nasdaq: LFVN) has launched its patent-pending MindBody GLP-1 System™ in the U.S., a dual-product solution designed to balance hunger hormones and support sustainable weight management. The system includes MB Core™ and MB Enhance™, which together increase natural GLP-1 production by an average of 140%.

Clinical trials showed that the system helped participants lose up to 27% of visceral fat and 5% of total body fat while maintaining muscle. The product launch at Market Connect in Kansas City met with high demand, with on-site products selling out quickly and e-commerce sales exceeding forecasts.

The MindBody GLP-1 System™ works by increasing GLP-1 production, activating GLP-1 receptor sites, and reducing the activity of enzymes that break down GLP-1. This approach aims to provide a comprehensive solution for long-term weight management and overall wellness.

LifeVantage (Nasdaq: LFVN) has announced enhancements to its Evolve Compensation Plan, set to launch on November 1, 2024, in the U.S., Japan, Australia, New Zealand, Canada, Mexico, and European markets. The updated plan aims to simplify and increase earning potential for independent LifeVantage Consultants.

Key features include:

• A new Sharing Bonus offering 10% commission for sharing LifeVantage products
• Double Sharing Bonus (up to 20%) for new Consultants in their first four months
• A bonus for reaching the Senior Consultant 1 rank

These changes are designed to provide greater simplicity and early income success for Consultants. The company also teased an upcoming launch of an innovative weight management system that naturally activates GLP-1.

LifeVantage (Nasdaq: LFVN) has completed a successful 12-week human clinical trial evaluating its innovative GLP-1 system for weight management. The study, involving 60 participants, assessed the system's impact on weight management, food cravings, and overall well-being. Participants were divided into three groups: product system alone, product system with diet and exercise guidance, and a control group.

Lisa Barnes, VP of Research, Development & Regulatory, expressed confidence in the system's ability to address weight management challenges through natural activation of GLP-1. The results will be shared at Market Connect in Kansas City, October 11-12, 2024, where the system will be revealed. CEO Steve Fife emphasized the company's commitment to delivering products that activate the body's natural processes. This trial, along with a recently completed in vitro study, marks a significant milestone in LifeVantage's efforts to expand its portfolio of activation products supporting cellular health.

LifeVantage (Nasdaq: LFVN) has announced positive in vitro results for its new GLP-1 system, designed to enhance weight management. The study, conducted on specialized L-cells in the colon, examined key genes involved in GLP-1 production and regulation. The two-product system showed synergistic gene activation, significantly increasing GLP-1 production through direct L-cell activation and gut microbiome optimization.

The research revealed downregulation of DPP-4 gene expression, allowing for more GLP-1 availability in the body. LifeVantage plans to introduce this innovative system in October, targeting new consumers and expanding market opportunities for its Consultants. The company emphasizes that these products are designed to activate optimal health processes at the cellular level, leveraging their unique Activation approach.

LifeVantage (Nasdaq: LFVN), a leading health and wellness company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY. Steve Fife, President and CEO, and Carl Aure, CFO, will represent the company, meeting with investors and delivering a presentation on Tuesday, September 10, 2024, at approximately 2:00 p.m. Eastern Time.

A live webcast of the presentation will be available on the company's Investor Relations website. The webcast replay will be accessible for about 90 days after the event. This conference participation highlights LifeVantage's commitment to engaging with investors and showcasing its products designed to activate optimal health processes at the cellular level.

LifeVantage (Nasdaq: LFVN) has announced the permanent addition of AXIO® Lemonade to its product lineup. Previously available as a -time offering, this fan-favorite flavor is now a permanent part of the AXIO energy drink range. AXIO Lemonade offers clean, sustained energy and focus through a nootropic blend of vitamins, minerals, and phytonutrients, without excess calories, sugar, or artificial additives.

The product aims to improve mental sharpness, elevate mood, and enhance stress resilience. CEO Steve Fife emphasized that this move represents LifeVantage's commitment to providing effective energy solutions that support an active lifestyle while delivering mental focus and stress resilience.

LifeVantage (Nasdaq: LFVN), a prominent health and wellness company, has announced a quarterly cash dividend of $0.04 per share of common stock. The dividend will be paid on September 17, 2024, to stockholders of record at the close of business on September 9, 2024. LifeVantage specializes in products designed to activate optimal health processes at the cellular level. This dividend declaration demonstrates the company's commitment to returning value to its shareholders and may indicate confidence in its financial stability and future prospects.

LifeVantage (Nasdaq: LFVN) reported financial results for Q4 and fiscal year 2024. Key highlights:

- Q4 revenue: $48.9 million, down 9.8% YoY
- FY2024 revenue: $200.2 million, down 6.2% YoY
- Q4 net income per diluted share: $0.10, down from $0.15 YoY
- FY2024 net income per diluted share: $0.23, up from $0.20 YoY
- FY2024 adjusted EBITDA: $17.0 million, up 44.7% YoY
- Strong balance sheet with $16.9 million cash and no debt

The company declared a cash dividend of $0.04 per share. For FY2025, LifeVantage projects revenue of $200-210 million, adjusted EBITDA of $18-21 million, and adjusted EPS of $0.70-$0.80.